Mount Lebanon Hospital

Beirut 470

0 studies enrolling now · 3 studies all time

What they study most

Crohn's Disease, First Line Non-Small Cell Lung Cancer, Follicular Lymphoma

Studies at this site

• A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease — Running, not enrolling
• Avelumab in First-line NSCLC (JAVELIN Lung 100) — Completed
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06) — Completed